Skip to main content
. 2019 Oct 29;10(59):6323–6333. doi: 10.18632/oncotarget.27259

Figure 7. RXDX-105 treatment leads to decreased angiogenesis in vivo.

Figure 7

(A) Drug treated tumor samples were noted to be less vascular and hemorrhagic on gross appearance and H&E staining. (B) Tumor samples were immunostained for vascular endothelial cells with anti-CD31 antibodies and photographed at 10× magnification. (C) Mean vessel density was calculated using the number of observed vessels per high power field and compared in both treated and untreated tumors.